Geographic Atrophy (GA) is a chronic progressive degeneration of the macula due to late-stage age-related macular degeneration (AMD). GA is a progressive, irreversible, and blinding disease that tends to affect both eyes. Nearly two-thirds of geographic atrophy cases are reported in people aged 80 years and above.
&nbsp;
Geographic Atrophy Epidemiological Segmentation&nbsp;
The Epidemiological Segmentation of Geographic Atrophy in 7MM from 2017 to 2030 is segmented as:-&nbsp;
<ul>
<li>Total Prevalent Cases of Geographic Atrophy</li>
<li>Total Diagnosed cases of Geographic Atrophy</li>
<li>Total Diagnosed cases of Geographic Atrophy by Age Distribution</li>
<li>Total Geographic Atrophy Cases by Visual Impairment</li>
<li>Treated cases of Geographic Atrophy</li>
</ul>
&nbsp;
<a style="background-color: transparent; color: #0047b2;" href="https://www.delveinsight.com/report-store/geographic-atrophy-ga-epidemiology-forecast" target="_blank" rel="noopener noreferrer">Geographic Atrophy Epidemiology</a>&nbsp;
<ul>
<li>The total diagnosed cases of Geographic Atrophy in 7MM in 2017 was 2,516,401</li>
<li>The total treated cases of Geographic Atrophy in 7MM in 2017 was 1,162,112</li>
</ul>
&nbsp;
<a style="background-color: transparent; color: #0047b2;" href="https://www.delveinsight.com/report-store/geographic-atrophy-ga-market" target="_blank" rel="noopener noreferrer">Geographic Atrophy Market</a>
Market Size of Geographic Atrophy in 7MM in 2017 was USD 276 million
&nbsp;
Geographic Atrophy Market Drivers
<ul>
<li>Increasing prevalence rate</li>
<li>Emerging novel treatment options</li>
<li>Patient-friendly Dosage Regimes</li>
</ul>
&nbsp;
Geographic Atrophy Market Barriers
<ul>
<li>Failure of Investigational Drugs</li>
<li>Limited knowledge of Geographic Atrophy</li>
<li>Lack of access to specialists</li>
<li>Lack of focus on visual restoration</li>
<li>Compliance and Adherence</li>
</ul>
&nbsp;
<a style="background-color: transparent; color: #0047b2;" href="https://www.delveinsight.com/report-store/geographic-atrophy-ga-pipeline-insight" target="_blank" rel="noopener noreferrer">Geographic Atrophy Emerging Drugs</a>
The emerging drugs of the Geographic Atrophy market are&nbsp;
<ul>
<li>Pegcetacoplan (APL-2)</li>
<li>Zimura (avacincaptad pegol)</li>
<li>ALK-001</li>
<li>HMR59 (AAVCAGsCD59)</li>
<li>Risuteganib</li>
<li>ElamipretideGT005</li>
<li>CPCB-RPE1</li>
<li>RO7171009 (RG6147)</li>
<li>IONIS-FB-LRx</li>
<li>OpRegen</li>
<li>Palucorcel (CNTO 2476)</li>
</ul>
&nbsp;And many others.&nbsp;&nbsp;
&nbsp;
Geographic Atrophy Key Players
The key players in the Geographic Atrophy market are
<ul>
<li>Apellis Pharmaceuticals</li>
<li>Iveric Bio (formerly Ophthotech Corporation</li>
<li>Alkeus Pharmaceuticals</li>
<li>Hemera Biosciences</li>
<li>Allegro Ophthalmics</li>
<li>Stealth BioTherapeutics</li>
<li>Gyroscope Therapeutics</li>
<li>Regenerative Patch Technologies</li>
<li>Roche (Genentech</li>
<li>Ionis Pharmaceuticals/Roche</li>
<li>CellCure Neurosciences (a subsidiary of Lineage Cell Therapeutics)</li>
<li>Janssen Research &amp; Development</li>
</ul>
&nbsp;And many others.&nbsp;
&nbsp;
Map the latest developments in <a style="background-color: transparent; color: #0047b2;" href="https://www.delveinsight.com/blog/geographic-atrophy-market-size" target="_blank" rel="noopener noreferrer">Geography Atrophy treatment landscape</a> through our blog

Geographic atrophy Market

Geographic atrophy Symptoms, Treatment, epidemiology, companies, drugs infographic is a short guide to understand the problem and market landscape.